Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Return on Assets (2016 - 2025)

Historic Return on Assets for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to 2.44%.

  • Northwest Biotherapeutics' Return on Assets fell 200.0% to 2.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.44%, marking a year-over-year decrease of 200.0%. This contributed to the annual value of 2.72% for FY2024, which is 6700.0% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Return on Assets is 2.44%, which was down 200.0% from 2.57% recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Return on Assets registered a high of 1.44% during Q1 2022, and its lowest value of 3.67% during Q2 2021.
  • Over the past 5 years, Northwest Biotherapeutics' median Return on Assets value was 2.35% (recorded in 2022), while the average stood at 2.39%.
  • Per our database at Business Quant, Northwest Biotherapeutics' Return on Assets plummeted by -10300bps in 2021 and then surged by 18600bps in 2022.
  • Over the past 5 years, Northwest Biotherapeutics' Return on Assets (Quarter) stood at 1.69% in 2021, then crashed by -39bps to 2.35% in 2022, then grew by 13bps to 2.05% in 2023, then fell by -29bps to 2.65% in 2024, then increased by 8bps to 2.44% in 2025.
  • Its last three reported values are 2.44% in Q3 2025, 2.57% for Q2 2025, and 2.8% during Q1 2025.